Features of regional relapses in the central zone after surgical treatment of highly differentiated thyroid cancer
- Authors: Gogieva E.K.1, Romanov I.S.1, Bokhyan V.Y.1, Ignatova A.V.1,2, Gabrava M.M.1, Zarenkova A.K.3, Safonova A.B.1, Batyrov K.A.1
-
Affiliations:
- N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Peoples’ Friendship University of Russia named after Patrice Lumumba
- Podolsk Regional Clinical Hospital Center for Outpatient Cancer Care
- Issue: Vol 13, No 2 (2023)
- Pages: 10-17
- Section: DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS
- Published: 12.09.2023
- URL: https://ogsh.abvpress.ru/jour/article/view/884
- DOI: https://doi.org/10.17650/2222-1468-2023-13-2-10-17
- ID: 884
Cite item
Full Text
Abstract
Introduction. Thyroid cancer is the most common malignant tumor of the endocrine system and comprises 33 % of malignant neoplasms of the head and neck. first echelon lymph nodes affected by this pathology are located in the central area of the neck. The metastatic process further advances into the lymph nodes in the lateral tissues of the neck. Currently, there is no consensus on the effectiveness of prophylactic central lymph node dissection and no conclusive criteria determining the risk of recurrence in the central zone.
Aim. The assessment of factors influencing the risk of regional recurrence in the central zone.
Materials and methods. The study included 30 patients with highly differentiated thyroid cancer, in whom metastatic nodes in the central zone were identified and verified during primary treatment. All patients previously underwent unilateral or 2-sided central lymph node dissection in various institutions. During the period of dynamic observation, these patients revealed regional recurrence in the central zone. patients were observed and treated for recurrence at the National medical Research Center of Oncology named after N.N. Blokhin of the ministry of Health of Russia.
Results. primary surgical treatment in a specialized oncological institution was performed in 21 (70 %) patients, in a general surgical medical institution – in 7 (23.3 %), in an endocrinological institution – in 2 (6.7 %) patients. when assessing the influence of the morphological type and variant of thyroid cancer on the risk of developing regional recurrence, no statistical significance was found. No statistically significant factors were found in the analysis of the influence of characteristics of the primary tumor, such as tumor size, multifocal lesion, vascular invasion, extrathyroidal spread, on the risk of regional recurrence. In 16 (53.3 %) patients, recurrence occurred in the paratracheal zone of the ipsilateral side, in 7 (23.3 %) patients in the paratracheal zone of the contralateral side, bilateral lesions were observed in 2 (6.67 %) cases. 3 (10 %) patients were diagnosed with transient parathyroid insufficiency, 1 (3.3 %) – permanent parathyroid insufficiency, 1 (3.3 %) – hematoma in the area of the postoperative wound, patient, 2 (6.6 %) – injury to the recurrent laryngeal nerve.
Conclusion. Residual metastatic lymph nodes after previous surgical treatment are the reason for performing a second operation, which carries both the risks of postoperative complications and the psychological burden on the patient. Thus, an adequate and radically performed primary surgical intervention is the key to reducing regional recurrences.
About the authors
E. Kh. Gogieva
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Author for correspondence.
Email: elizagogieva535@gmail.com
ORCID iD: 0000-0001-6007-0885
Eliza Hampashevna Gоgieva
24 Kashirskoe Shosse, Moscow 115522
Russian FederationI. S. Romanov
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-5421-5985
24 Kashirskoe Shosse, Moscow 115522
Russian FederationV. Yu. Bokhyan
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-9066-5190
24 Kashirskoe Shosse, Moscow 115522
Russian FederationA. V. Ignatova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Peoples’ Friendship University of Russia named after Patrice Lumumba
Email: fake@neicon.ru
ORCID iD: 0000-0002-6796-0968
24 Kashirskoe Shosse, Moscow 115522
6 Miklukho-Maklaya St., Moscow 117198
Russian FederationM. M. Gabrava
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0003-3629-8438
24 Kashirskoe Shosse, Moscow 115522
Russian FederationA. K. Zarenkova
Podolsk Regional Clinical Hospital Center for Outpatient Cancer Care
Email: fake@neicon.ru
ORCID iD: 0000-0002-3095-0088
Bld. 1, 9 Parkovy proezd, Kuznechiki village, Podolsk 142110
Russian FederationA. B. Safonova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0009-0000-6927-1966
24 Kashirskoe Shosse, Moscow 115522
Russian FederationK. A. Batyrov
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0009-0003-8502-1256
24 Kashirskoe Shosse, Moscow 115522
Russian FederationReferences
Supplementary files


